Clinical Trial Update: Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Alpha-TEA in combination with trastuzumab for refractory HER2-positive metastatic breast cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpha-TEA (alpha-tocopheryl ether acetate)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Veana Therapeutics | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 1 | Status: SUSPENDED